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Background: Parotidectomy is the primary treatment for parotid gland tumors. However, complications 
may include a prominent facial scar or infra-auricular depressed deformity, Frey’s syndrome, first bite 
syndrome, or other facial pain, numbness, and paralysis. Acellular dermal matrix (ADM) has been widely 
used to prevent these complications in parotid surgery, but there have been no prospective, multi-center 
trials documenting its efficacy. This study evaluates the effectiveness of ADM implantation in preventing 
infra-auricular depressed deformity, Frey’s syndrome and first bite syndrome after parotidectomy.
Methods: We analyzed 51 cases of standard parotidectomy and 58 cases of parotidectomy with implantation 
of Megaderm™ ADM through prospective multicenter trial. Acute complications including infection, 
seroma, hematoma, skin necrosis, and acute parotid area pain were evaluated 1 week postoperatively. 
Clinician grading of Frey’s syndrome and blinded clinician evaluation of infra-auricular depressed deformities 
were conducted at 3, 6, and 12 months. Patients evaluated subjective satisfaction with neck appearance, Frey’s 
syndrome quality, and acute parotid area pain at 3, 6, and 12 months.
Results: There was a higher incidence of seroma in the Megaderm™ group than in the control group 
at week 1. The incidence and total clinician-evaluated Frey’s syndrome scores were significantly lower in 
the Megaderm™ group than in the control group at 3, 6, and 12 months. Both the objective and subjective 
evaluations of the facial contour showed a better outcome in the Megaderm™ group compared to the 
control group at 3, 6, and 12 months. There were no significant differences between the groups in the 
patient-reported Frey’s syndrome quality scores at 3, 6, and 12 months, but the Megaderm™ group reported 
significantly less acute pain than the control group.
Conclusions: ADM implantation can effectively reduce the occurrence of Frey’s syndrome, infra-auricular 
depressed deformity, and first bite syndrome after parotidectomy. ADM may be especially advantageous in 
complex parotidectomy cases when significant complications are expected.
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Introduction
Parotidectomy is the primary treatment for parotid gland 
tumors. However, parotidectomy can cause considerable 
complications including a prominent facial scar or infra-
auricular depressed deformity, gustatory sweating, facial 
pain, numbness and paralysis (1). Most parotidectomy 
patients, especially young women, are concerned about 
postoperative changes in facial appearance, which can have 
adverse effects on patients’ mental status. Recently, the 
facial scar problem has been somewhat resolved with the 
modified facelift incision method (2). However, preventing 
an infra-auricular depressed deformity continues to be a 
challenge, particularly in total parotidectomy. 
In addition, patients undergoing parotidectomy 
occasionally complain about flushing, sweating, or intense 
pain in the parotid region during food intake, which may be 
attributed to Frey’s syndrome (3). It results from aberrant 
regeneration of parasympathetic nerve fibers within the 
parotid gland to the overlying sweat glands of the skin (4). 
Rarely, patients with parotidectomy suffer acute facial pain 
at the first bite of each meal, which is aptly termed “First 
bite syndrome” (5). All of these complications have negative 
effects on patients’ quality of life.
Current surgical methods for preventing depressed 
deformities and Frey’s syndrome include dermo-fat graft, 
temporalis myofascial flap, and sternocleidomastoid 
muscle flap (6-10). However, these autologous tissue 
transplantations have problems such as additional surgical 
donor site trauma, increased operating time, and a limited 
donor quantity (11). Since the early 1990s, acellular dermal 
matrix (ADM) has been developed and utilized for various 
head and neck reconstructions (12). ADM is obtained from 
human cadaver skin by solvent, detergent, and freeze-drying 
processes to eliminate cellular components (13). It consists 
of an extracellular matrix and basement membrane which is 
sterile and non-immunogenic.
In parotid surgery, ADM has proven useful for the 
space-occupying effect and prevention of Frey’s syndrome 
(14,15). However, previous studies have shown insignificant 
results due to retrospective designs or small numbers of 
patients, and there have been no prospective and large-
scale clinical trials for ADM use with parotid surgery. 
Therefore, we performed a multi-center prospective trial 
to evaluate the effectiveness of Megaderm™ ADM for the 
prevention of infra-auricular depressed deformities, Frey’s 
syndrome, and first bite syndrome following parotid tumor 
surgery. 
We present the following article in accordance with the 




This multi-center prospective clinical trial was carried out at 
6 tertiary head and neck centers (Ajou University Hospital, 
Cheonan Soonchunhyang University Hospital, Gangnam 
Severance Hospital, Inha University Hospital, International 
St. Mary’s Hospital, and Severance Hospital). 
The trial was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). The study 
was approved by the institutional review boards of Ajou 
University, Cheonan Soonchunhyang University, Gangnam 
Severance Hospital, Inha University, International St. 
Mary’s Hospital, Severance Hospital and informed consent 
was taken from all individual participants.
Patients 
Between November 2015 and March 2018, patients with 
benign parotid tumors who underwent superficial or total 
parotidectomy by experienced head and neck surgeons 
were considered eligible. The exclusion criteria ruled out 
patients who were younger than 18 or older than 70 years, 
had a malignant tumor at final histology, a history of keloid 
scarring, a current pregnancy, recurrent parotid tumors, 
previous parotid surgery, or an uncontrolled medical illness. 
Surgical procedure
A modified facelift incision method was used through the 
skin, subcutaneous tissue, and platysma in all patients. The 
skin flap was raised under the parotid fascia to the anterior 
border of the masseter muscle, and superficial or total 
parotidectomy was performed in all participating hospitals. 
In the case with implantation of Megaderm™ (L & C BIO 
Corp., Seongnam-si, Korea), a 5 cm × 8 cm sheet was used 
in single-layer grafts or folding grafts according to the 
surgeon’s decision (Figure 1). Megaderm™ was trimmed 
to the proper size and shape based on the size of the 
depression and inserted between the flap in the parotid bed 
and the residual parotid tissue. All patients had a Hemo-
vac drain inserted during surgery and removed when the 
amount of drainage was less than 20 cc. 
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Allocation
All of the participants were then allocated into two groups. 
Half of the enrolled patients underwent parotidectomy 
with implantation of Megaderm™ (L & C BIO Corp., 
Seongnam-si, Korea). The other patient group underwent 
parotidectomy alone without Megaderm™ implantation. 
The use of Megaderm™ was decided by choice of patients 
with the recommendation of the surgeon. The surgeon 
performed the implantation of Megaderm™ only on the 
agreed patients. The patients purely determined the use 
of MegadermTM because of the economic burden of the 
Megaderm™ and the fact that the external material is 
inserted into the patient’s body.
Outcome measures
Preoperative data including age, gender, body mass index 
(BMI), underlying disease, allergic history, and pathologic 
tumor type were collected. Follow-up examinations were 
carried out at 1 week, and 3, 6, and 12 months postoperatively. 
The evaluation of acute complications including infection, 
seroma, hematoma, skin necrosis, and acute parotid area pain 
was performed 1 week postoperatively. Grading of Frey’s 
syndrome was performed at 3, 6, and 12 months (Table 1). 
The iodine-starch test was performed at each follow-up visit. 
Objective evaluation of infra-auricular depressed deformities 
was performed by two independent, blinded physicians using 
a visual analog scale of contouring deformity based on facial 
photos taken from the anterior, head-elevating, lateral, and 
oblique views (1, undetectable deformity; 2, mild deformity; 
3, moderate deformity; 4, severe deformity; 5, extremely 
severe deformity). At 3, 6, and 12 months, each patient also 
filled in a questionnaire that included a subjective satisfaction 
score of gross neck appearance (Score 1–5; 5 being the most 
satisfactory); quality of Frey’s syndrome (Scores 1–4: 1, hardly 
ever; 2, sometimes and tolerable; 3, regular and unpleasant; 
4, often and annoying); and acute parotid area pain using a 
visual analog scale (scores 1–10; 10 being the most severe).
Statistical analysis
An unpaired t-test and chi-square test were used for 
descriptive analysis and Pearson’s chi-square test and 
Fisher’s exact test were used for qualitative variables. A P 
value less than 0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software, 
version 22.0 (IBM Corporation, USA).
Results
Patient characteristics
A total of 134 patients were enrolled, with 25 patients lost 
to follow-up, 109 patients (58 Megaderm™ group and 
51 control group) completing all follow-up examinations. 
There were 59 males and 50 females with a mean age of 
42.5±4.8 years (range, 21 to 67 years). There were no 
B CA
Figure 1 The implantation of ADM (acellular dermal matrix) following total parotidectomy. (A) Preoperative photo shows the modified 
facelift incision method that was used. (B) Intraoperative view shows the surgical field after total parotidectomy with preservation of the 
facial nerve. (C) The ADM is designed and inserted between the parotid bed flap and the residual parotid tissue.
Table 1 Clinician evaluation of Frey’s syndrome
Variable Grading [score]
Frey’s symptoms Yes [1]/no [0]
Affected area 0.1–2 cm [1]/2.1–4 cm [2]/>4 cm [3]
Excessive focal sweating Yes [3]/no [0]
Unpleasant smell Yes [3]/no [0]
Total score 0–10 
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statistically significant differences in patient characteristics 
and pathologic distribution of the two groups (Table 2). 
Acute postoperative complications
Complications were observed in 38/109 (34.8%) patients 
at 1 week postoperatively. The most common acute 
complication (20 patients, 18.3%) was seroma (Table 3). The 
rate of seroma complications at postoperative week 1 was 
significantly higher in the Megaderm™ group compared 
with the control group. However, there was no significant 
difference between the groups in the rate of any other 
complications.
Effect on Infra-auricular depressed deformity 
The appearance of the infra-auricular depressed deformity 
was assessed using a contouring deformity VAS and 
subjective satisfaction score at 3, 6, and 12 months after 
parotidectomy. The contouring deformity VAS of the 
Megaderm™ group compared with the control group was 
significantly lower at 3, 6, and 12 months. The subjective 
satisfaction scores of the Megaderm™ group were also 
significantly higher than in the control group at 3, 6, and 
12 months after parotidectomy (Table 4). 
Effect on Frey’s syndrome
According to patients’ reported symptoms, 17 (15.5%), 
16 (14.6%), and 12 (11%) of the 109 patients experienced 
Frey’s syndrome at 3, 6, and 12 months after parotidectomy, 
respectively. Significant decreases in the incidence and 
total clinician calculated Frey’s syndrome score at 3, 6, and 
12 months after surgery were observed in the Megaderm™ 
group. However, there was no difference between groups in 
the patient reported Frey’s syndrome quality scores at 3, 6, 
and 12 months (Table 5).
Effect on first bite syndrome
The Megaderm™ group reported significantly lower rates 
of acute pain during the past 3 months and pain VAS scores 
compared with those in the control group at 3, 6, and 
12 months after parotidectomy (Table 6).
Discussion
Parotidectomy is commonly thought to be a burdensome 
surgery because of potential complications that adversely 
affect patients’ daily life. Common complications associated 
with parotidectomy are facial nerve injury, facial numbness, 
asymmetric facial contour, gustatory sweating, and 
postprandial facial pain (1).
Frey’s syndrome and an infra-auricular depressed 
deformity are two complications that may be prevented by 
similar methods. Frey’s syndrome occurs by the aberrant 
regeneration of sectioned parasympathetic fibers, which 
re-grow to the sympathetic nerve fibers that control the 
subcutaneous sweat glands and vessels. Based on the above 
pathophysiology, Frey’s syndrome is believed to be prevented 
by blocking aberrant innervations with a barrier between the 
skin flap and the remnant parotid tissue (6,7). Infra-auricular 
depressed deformity is almost always observed in total 
parotidectomy patients due to the loss of profuse parotid 
tissue. Over the years, various autologous tissue interposition 
methods have been reported to reduce the incidence of both 
Frey’s syndrome and depressed deformity (6-10). However, 
autologous tissue interposition has various drawbacks, such as 
the need for additional donor sites, increased operation time, 
limited donor sources, and the possibility of postoperative 
complications and resorption (11).
ADM was first used in full-thickness burns by Livesey 
et al. in 1995 (16). Since then, ADM implantation is 
gradually replacing autologous tissue interposition owing 
to the ease of trimming, variability in size and thickness, 
and avoidance of donor site morbidity in head and neck 
reconstruction (11,12). However, most studies of ADM in 
parotidectomy have been retrospective and observational 
in design. This study is significant as the first multi-center 
prospective trial to investigate the effect of ADM on 
chronic complications of parotidectomy.
In this study, the incidence and total Frey’s syndrome 
score following parotidectomy in the Megaderm™ group 
were significantly lower compared with those in the control 
group at 3, 6, and 12 months. Also, the objective and 
subjective evaluation of the facial contour showed a better 
outcome in the Megaderm™ implantation group compared 
with those in the control group at 3, 6, and 12 months. 
ADM is derived from human cadaveric skin and consists 
of basement membrane and collagen-based connective 
tissue without cellular and immunogenic components (17). 
The main mechanisms of ADM implantation are based 
on fibroblast infiltration and neo-vascularization. In the 
application to fill dead space, it induces cellular infiltration 
by macrophages, finally leading to tissue generation and 
revascularization within the host (18). ADM has been 
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Table 2 Patient demographic and clinical characteristics by group
Variables
ADM (n=58) Control (n=51) Total (n=109)
P value
N % N % N %
Sex
Male 27 46.5 32 62.7 59 54.1 0.066
Female 31 53.4 19 37.2 50 45.8
Age (years)
20–29 10 17.2 5 9.8 15 13.7 0.487
30–39 14 24.1 15 29.4 29 26.6
40–49 12 20.6 13 25.4 25 22.9
50–59 14 24.1 13 25.4 27 24.7
60–69 8 13.7 5 9.8 13 11.9
BMI
Under weight 1 1.7 0 0 1 0.91 0.287
Normal weight 21 36.2 20 39.2 41 37.6
Overweight 17 29.3 20 39.2 37 33.9
Obese 12 20.6 10 19.6 22 20.1
Extremely obese 7 12 1 1.9 8 7.3
Smoking
Yes 13 22.4 16 31.3 29 26.6 0.206
No 45 77.5 35 68.6 80 73.3
Allergy
Yes 2 3.40 3 5.8 5 4.58 0.671
No 56 96.7 48 94.1 104 95.4
Drug hypersensitivity
Yes 2 3.44 2 3.92 4 3.66 0.308
No 56 96.5 49 96.0 105 96.3
Operation
Superficial 58 100 50 98 108 99 0.705
Total 0 0 1 1.96 1 1
Pathologic diagnosis
Pleomorphic adenoma 36 62 35 68.6 71 65.1 0.781
Warthin 17 29.3 13 25.4 30 27.5
Oncocytoma 3 5.17 2 3.92 5 4.58
Basal cell adenoma 1 1.72 1 1.96 2 1.83
Miscellaneous 1 1.72 0 0 1 0.91
ADM, acellular dermal matrix; BMI, body mass index.
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Table 3 Surgical complications at 1 week postoperative
Variables
ADM (n=58) Control (n=51) Total (n=109)
P value
N % N % N %
Infection 2 3.44 1 1.96 3 2.75 1.00
Seroma 14 24.1 6 11.7 20 18.34 0.022
Hematoma 5 8.62 4 7.84 9 8.25 0.182
Skin necrosis 0 0 0 0 0 0
Acute pain 3 5.17 5 9.8 8 7.33 0.28
Allergic reaction 0 0 0 0 0 0
ADM, acellular dermal matrix.
Table 4 Visual analogue scale for the contouring deformity and subjective satisfaction scores for both patient groups
Contouring deformity
Month 3 Month 6 Month 12
ADM Control ADM Control ADM Control
1. Undetectable deformity 31 8 25 5 22 4
2. Mild deformity 26 23 32 22 34 23
3. Moderate deformity 4 15 4 16 5 16
4. Severe deformity 0 7 0 10 0 10
5. Extremely severe deformity 0 1 0 1 0 1
SSS 4.26±0.51 3.78±0.97 4.16±0.32 3.63±0.92 3.96±0.54 3.57±0.86
P value (VAS/SSS) 0.001/0.001 0.001/0 0.001/0
ADM, acellular dermal matrix; VAS, visual analogue scale; SSS, subjective satisfaction score.
Table 5 Patient evaluation of Frey’s syndrome in both groups
Variables
Month 3 Month 6 Month 12
ADM Control ADM Control ADM Control
Patients (%) 3 (5.17) 14 (27.4) 4 (6.89) 12 (23.5) 4 (6.89) 8 (15.6)
Total pain score [0–10] 0.23±1.2 3.48±1.54 0.36±1.31 3.57±1.1 0.28±1.19 3.64±0.85
Frey’s quality [1–4] 1.05±0.34 2.13±0.48 1.25±0.24 2.36±0.78 1.32±1.15 1.41±0.78
P value 0.032/0.027/0.095 0.037/0.024/0.315 0.018/0.024/0.287
ADM, acellular dermal matrix.
Table 6 Evaluation of First bite syndrome pain in parotidectomy patients in both groups 
Variables
Month 3 Month 6 Month 12
ADM Control ADM Control ADM Control
Acute pain in past 3M 1.72±1.17 3.04±2.25 1.48±1.45 4.25±2.73 0.72±1.82 2.85±1.59
Pain VAS 0.90±1.4 2.93±2.0 1.52±1.36 2.571.63 1.02±0.89 1.85±1.38
P value (No./VAS) 0/0.002 0.023/0.01 0.034/0.02
ADM, acellular dermal matrix; M, month; No., number; VAS, visual analogue scale. 
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used as an interposition barrier and tissue augmentation 
substitute in parotidectomy, and the type IV collagen in the 
dermal matrix serves to block the misconnected in-growth 
of the nerve fibers (19). 
In this study, patients with Megaderm™ implants 
had less acute pain and a lesser pain VAS score during 
eating compared with those in the control group at 3, 
6, and 12 months. One of the common complications 
of parotidectomy, First bite syndrome, presents as acute 
and sharp pain at the first mastication of a meal following 
parapharyngeal surgery or deep lobe parotid surgery. It is 
caused by loss of sympathetic innervations to the parotid 
gland and subsequent cross-stimulation of parasympathetic 
neurotransmitters released by mastication. There are 
several treatment options for first bite syndrome, such 
as medication, tympanic neurectomy, and botulinum 
toxin type A (BTA) injection. However, efficacy of these 
therapies has not been fully demonstrated. BTA intra-
parotid injection has recently been introduced as the most 
safe and effective method for the management of first bite 
syndrome (20). The effectiveness is thought be due to 
a blockade of the neurotransmitters that induce intense 
myoepithelial contractions. Similarly, ADM can reduce the 
intensity and incidence of first bite syndrome by blockage 
of neurotransmitters. 
Our study suggests that Megaderm™ implantation 
was associated with an increased rate of seroma at 1week 
postoperatively. The reason for this is uncertain. One 
hypothesis is that seroma results from a disturbance of saliva 
reabsorption caused by interactions with Megaderm™ and 
remnant parotid tissue (17). We suggest that Hemovac use is 
particularly important to prevent seroma with Megaderm™ 
implantation.
The primary limitation of this study is the low number 
of patients with total parotidectomy. Thus, a comparative 
analysis of superficial and total parotidectomy could not be 
performed. Moreover, the postoperative follow-up period in 
this study was 1 year, which may not be adequate to verify 
the long-term effects of Megaderm™ application and any 
long-term complications such as resorption and foreign 
body sensation. Many clinical studies have demonstrated 
the effectiveness of Megaderm™ for preventing infra-
auricular depressed deformities and Frey’s syndrome after 
parotidectomy (11,12). However, this multi-center study 
is the first to prospectively investigate the usefulness 
of Megaderm™ in regard to various parotidectomy 
complications. 
Megaderm™ implants are available in various sizes, 
avoid the problem of donor site morbidity, and lead to 
fewer complications than parotidectomy without ADM. 
Megaderm™ implantation in parotidectomy is a safe and 
effective method for preventing infra-auricular depressed 
deformity, Frey’s syndrome, and first bite syndrome. 
Megaderm™ implantation may be especially advantageous 
in complex parotidectomy with significant complications 
expected.
Acknowledgments
Funding: This study was supported by a faculty research 
grant of Yonsei University College of Medicine (6-2020-
0144).
Footnote
Reporting Checklist: The authors have completed the 
CONSORT reporting checklist. Available at http://dx.doi.
org/10.21037/gs-20-703
Data Sharing Statement:  Available at http://dx.doi.
org/10.21037/gs-20-703
Peer Review File: Available at http://dx.doi.org/10.21037/gs-
20-703
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/gs-20-703). The authors have no conflicts of 
interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. The trial was 
conducted in accordance with the Declaration of Helsinki 
(as revised in 2013). The study was approved by the 
institutional review boards of Ajou University, Cheonan 
Soonchunhyang University, Gangnam Severance Hospital, 
Inha University, International St. Mary’s Hospital, Severance 
Hospital (No. 4-2014-0848) and informed consent was 
taken from all individual participants. 
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
677Gland Surgery, Vol 10, No 2 February 2021
© Gland Surgery. All rights reserved.   Gland Surg 2021;10(2):670-677 | http://dx.doi.org/10.21037/gs-20-703
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Erkan AN, Yavuz H, Ozer C, et al. Quality of life after 
surgery for benign disease of the parotid gland. J Laryngol 
Otol 2008;122:397-402.
2. Grover N, D'Souza A. Facelift approach for parotidectomy: 
an evolving aesthetic technique. Otolaryngol Head Neck 
Surg 2013;148:548-56. 
3. Fiacchini G, Cerchiai N, Tricò D, et al. Frey Syndrome, 
First Bite Syndrome, great auricular nerve morbidity, 
and quality of life following parotidectomy. Eur Arch 
Otorhinolaryngol 2018 Jul;275:1893-902. 
4. Glaister DH, Hearnshaw JR, Heffron PF, et al. The 
mechanism of post-parotidectomy gustatory sweating (the 
auriculo-temporal syndrome). Br Med J 1958;2:942-6. 
5. Linkov G, Morris LG, Shah JP, et al. First bite syndrome: 
incidence, risk factors, treatment, and outcomes. 
Laryngoscope 2012;122:1773-8. 
6. Sanabria A, Kowalski LP, Bradley PJ, et al. 
Sternocleidomastoid muscle flap in preventing Frey's 
syndrome after parotidectomy: a systematic review. Head 
Neck 2012;34:589-98. 
7. Clayman MA, Clayman SM, Seagle MB. A review of the 
surgical and medical treatment of Frey syndrome. Ann 
Plast Surg 2006;57:581-4. 
8. Fasolis M, Zavattero E, Iaquinta C, et al. Dermofat graft 
after superficial parotidectomy to prevent Frey syndrome 
and depressed deformity. J Craniofac Surg 2013;24:1260-2. 
9. Rubinstein RY, Rosen A, Leeman D. Frey syndrome: 
treatment with temporoparietal fascia flap interposition. 
Arch Otolaryngol Head Neck Surg 1999;125:808-11. 
10. Liu DY, Tian XJ, Li C, et al. The sternocleidomastoid 
muscle flap for the prevention of Frey syndrome and 
cosmetic deformity following parotidectomy: A systematic 
review and meta-analysis. Oncol Lett 2013;5:1335-42.
11. Luo W, Zheng X, Chen L, et al. The use of human 
acellular dermal matrix in the prevention of infra-auricular 
depressed deformities and Frey's syndrome following total 
parotidectomy. Oral Surg Oral Med Oral Pathol Oral 
Radiol 2012;114:e9-13. 
12. Shridharani SM, Tufaro AP. A systematic review of acelluar 
dermal matrices in head and neck reconstruction. Plast 
Reconstr Surg 2012;130:35S-43S. 
13. Kim YS, Na YC, Yoon HS, et al. Short-term changes of 
human acellular dermal matrix (Megaderm) in a mouse 
model. Arch Craniofac Surg 2019;20:10-6. 
14. Ye WM, Zhu HG, Zheng JW, et al. Use of allogenic 
acellular dermal matrix in prevention of Frey's 
syndrome after parotidectomy. Br J Oral Maxillofac Surg 
2008;46:649-52.
15. Sachsman SM, Rice DH. Use of AlloDerm implant to 
improve cosmesis after parotidectomy. Ear Nose Throat J 
2007;86:512-3. 
16. Livesey SA, Herndon DN, Hollyoak MA, et al. 
Transplanted acellular allograft dermal matrix. Potential 
as a template for the reconstruction of viable dermis. 
Transplantation 1995;60:1-9.
17. Athavale SM, Phillips S, Mangus B, et al. Complications 
of alloderm and dermamatrix for parotidectomy 
reconstruction. Head Neck 2012;34:88-93. 
18. Athavale SM, Rangarajan S, Dharamsi L, et al. 
AlloDerm and DermaMatrix implants for parotidectomy 
reconstruction: a histologic study in the rat model. Head 
Neck 2013;35:242-9.
19. May JS, McGuirt WF. Frey's syndrome: treatment with 
topical glycopyrrolate. Head Neck 1989;11:85-9. 
20. Ghosh A, Mirza N. First bite syndrome: Our experience 
with intraparotid injections with botulinum toxin type A. 
Laryngoscope 2016;126:104-7. 
Cite this article as: Kim JH, Kim DH, Lim JY, Won HR, 
Shin YS, Kim CH, Ban MJ, Park JH, Byeon HK, Hong HJ, 
Choi EC, Koh WY. Effect of human acellular dermal matrix 
(Megaderm™) on infra-auricular depressed deformities, Frey’s 
syndrome, and first bite syndrome following parotidectomy: a 
multi-center prospective study. Gland Surg 2021;10(2):670-677. 
doi: 10.21037/gs-20-703
